First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report
Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-expressing metastatic pulmonary carcinoid tumor, a cl...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324001206 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169474211119104 |
|---|---|
| author | Alissa J. Cooper, MD Natasha Rekhtman, MD, PhD Marina K. Baine, MD, PhD Marie C. Thomas, DNP, FNP-C Alia C. Lynch, PharmD, BCOP Ryan D. Gentzler, MD, MS |
| author_facet | Alissa J. Cooper, MD Natasha Rekhtman, MD, PhD Marina K. Baine, MD, PhD Marie C. Thomas, DNP, FNP-C Alia C. Lynch, PharmD, BCOP Ryan D. Gentzler, MD, MS |
| author_sort | Alissa J. Cooper, MD |
| collection | DOAJ |
| description | Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-expressing metastatic pulmonary carcinoid tumor, a clinical entity without many approved management options. Here, we report the case of a patient with metastatic atypical carcinoid tumor which had progressed on multiple previous therapies. Her tumor strongly expressed DLL3 protein and had clinical response to tarlatamab therapy. This case indicates that this novel therapy may be an efficacious option in other pulmonary neuroendocrine cancers. |
| format | Article |
| id | doaj-art-a8288d90bce449ed811d1abf0dde896c |
| institution | OA Journals |
| issn | 2666-3643 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-a8288d90bce449ed811d1abf0dde896c2025-08-20T02:20:44ZengElsevierJTO Clinical and Research Reports2666-36432024-12-0151210075010.1016/j.jtocrr.2024.100750First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case ReportAlissa J. Cooper, MD0Natasha Rekhtman, MD, PhD1Marina K. Baine, MD, PhD2Marie C. Thomas, DNP, FNP-C3Alia C. Lynch, PharmD, BCOP4Ryan D. Gentzler, MD, MS5Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, New YorkDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New YorkDivision of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VirginiaDivision of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VirginiaDepartment of Pharmacy Services, UVA Health, Charlottesville, Virginia; Corresponding author. Address for correspondence: Ryan D. Gentzler, MD, MS, University of Virginia, PO Box 800716, Charlottesville, Virginia 22908.Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-expressing metastatic pulmonary carcinoid tumor, a clinical entity without many approved management options. Here, we report the case of a patient with metastatic atypical carcinoid tumor which had progressed on multiple previous therapies. Her tumor strongly expressed DLL3 protein and had clinical response to tarlatamab therapy. This case indicates that this novel therapy may be an efficacious option in other pulmonary neuroendocrine cancers.http://www.sciencedirect.com/science/article/pii/S2666364324001206CarcinoidNeuroendocrineTarlatamabCase report |
| spellingShingle | Alissa J. Cooper, MD Natasha Rekhtman, MD, PhD Marina K. Baine, MD, PhD Marie C. Thomas, DNP, FNP-C Alia C. Lynch, PharmD, BCOP Ryan D. Gentzler, MD, MS First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report JTO Clinical and Research Reports Carcinoid Neuroendocrine Tarlatamab Case report |
| title | First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report |
| title_full | First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report |
| title_fullStr | First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report |
| title_full_unstemmed | First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report |
| title_short | First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report |
| title_sort | first report of response to tarlatamab in a patient with dll3 positive pulmonary carcinoid case report |
| topic | Carcinoid Neuroendocrine Tarlatamab Case report |
| url | http://www.sciencedirect.com/science/article/pii/S2666364324001206 |
| work_keys_str_mv | AT alissajcoopermd firstreportofresponsetotarlatamabinapatientwithdll3positivepulmonarycarcinoidcasereport AT natasharekhtmanmdphd firstreportofresponsetotarlatamabinapatientwithdll3positivepulmonarycarcinoidcasereport AT marinakbainemdphd firstreportofresponsetotarlatamabinapatientwithdll3positivepulmonarycarcinoidcasereport AT mariecthomasdnpfnpc firstreportofresponsetotarlatamabinapatientwithdll3positivepulmonarycarcinoidcasereport AT aliaclynchpharmdbcop firstreportofresponsetotarlatamabinapatientwithdll3positivepulmonarycarcinoidcasereport AT ryandgentzlermdms firstreportofresponsetotarlatamabinapatientwithdll3positivepulmonarycarcinoidcasereport |